



Product:	MRx-4DP0004
Protocol Number:	MRx-4DP0004-II-001
EudraCT No:	2020-001597-30
Study title:	A pilot, multiple dose study to evaluate the safety and efficacy of MRx-4DP0004 (a lyophilised formulation of Bifidobacterium breve, proprietary strain of 4D Pharma Research) in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)
Sponsor:	4D Pharma plc.

To Whom it May Concern

The above mentioned trial with protocol number MRx-4DP0004-II-001 was early terminated on 03 June 2021. No subjects were recruited and no treatment was administered in the United Kingdom (UK) and globally.

The early termination is due to difficulties in recruitment of hospitalised patients with symptoms indicative of COVID-19 for the trial. This early termination has no consequence or impact to the evaluation of results and overall risk benefit assessment of the IMP.

No results will therefore be available to be published in EudraCT for the study protocol.

Signed *A.L. Mahim*

Dated 31 Aug 2021